When Kristelle Dammarell founded Genoscience in Sarasota, Florida, she was entering a market that had long rewarded opacity, where researchers routinely received peptides of uncertain origin, inconsistent purity, and no reliable documentation to support their work.
The research chemicals market had a structural problem: most domestic laboratories depended either on unverified overseas suppliers or on institutional-grade sources priced far beyond their budgets. Dammarell saw that gap not as a commercial opportunity in the conventional sense, but as a quality-control failure with real consequences for scientific reproducibility. Under her leadership, Genoscience built its entire operating model around solving that problem through cGMP-compliant manufacturing, third-party verification, and a transparency standard largely absent from the market at the time.
Every compound in the Genoscience catalog undergoes High-Performance Liquid Chromatography and Mass Spectrometry testing. Certificates of Analysis are made publicly available, allowing researchers to confirm purity and molecular weight before beginning any study. That level of documentation is not standard practice in this sector. At Genoscience, it is the baseline.
Building Trust Through Education, Not Marketing
Dammarell made an early decision that has shaped the company’s identity: that credibility in the research community is built through education, not promotion. Genoscience developed detailed research guides, handling protocols, and compliance documentation, not to drive purchasing decisions, but to help researchers understand what they are working with and why handling standards matter for reproducible results.
That approach repositioned the company from a transactional supplier into a knowledge resource. Researchers who consult Genoscience’s materials are not being sold to; they are being equipped. The distinction has proven meaningful. Long-term customer retention has grown, and the company’s reputation within the scientific community has followed.
“Trust in this sector has to be earned through education rather than marketing,” Dammarell has noted. The company’s operational record consistently reflects that conviction, from the depth of its product documentation to the breadth of its catalog, which includes compounds such as BPC-157, TB-500, Retatrutide, and Thymosin Alpha 1, covering metabolic, CNS signaling, and cellular senescence research applications.
Photo Courtesy of M. Azraq
A Supply Chain Designed Around Research Continuity
One of Genoscience’s more practical contributions to the field is its domestic logistics model. Lyophilized peptides require careful temperature management throughout the supply chain, and international sourcing has long introduced customs delays, inconsistent handling, and thermal degradation that disrupts research timelines. By maintaining a controlled domestic shipping operation, Genoscience addresses a problem that laboratories have long faced without a reliable solution.
The company also introduced a subscription model that allows research facilities to automate recurring peptide orders at pricing up to 60 percent below standard rates. For laboratories conducting longitudinal studies, supply continuity is as critical as purity consistency. The subscription structure eliminates the risk of mid-study interruptions, a straightforward fix to a problem that has historically forced researchers to delay or restart work.
Dammarell framed the subscription model as a structural improvement rather than a sales mechanism, and the outcomes have supported that framing. Adoption has been steady, and the growth it has produced reflects what happens when a company builds its services around what researchers actually need rather than around what is easiest to offer.
Recognition That Reflects A Documented Record
Genoscience received a 2026 Global Recognition Award, earning distinction across six categories: Innovation, Workplace Culture, Startup of the Year, Customer Experience, Service, and Research. The evaluation process used by Global Recognition Awards includes eligibility screening by independent industry experts and a final assessment using the Rasch model, which constructs a linear measurement scale that allows precise comparisons across nominees in different performance areas.
Genoscience’s application was supported by independent third-party testing through Janoshik Analytical, verification of cGMP manufacturing standards, and documented operational performance across its product line. The recognition was not based solely on self-reported claims; it was corroborated by the company’s external testing records and compliance documentation.
Alex Sterling, a spokesperson for Global Recognition Awards, noted that “Genoscience exemplifies what this award is designed to recognize: a company that has achieved genuine excellence not by cutting corners, but by doing the harder work of building trust through transparency, scientific rigor, and a real commitment to the research community it serves.” For a startup entering one of the more skeptical corners of the scientific supply market, that kind of documented credibility is not incidental. It is the entire model, and Genoscience’s sustained progress offers a clear illustration of what principled, research-centered leadership can achieve in a demanding industry.
Important Legal & Safety Notice: All compounds discussed are intended for in-vitro research and analytical use only. They are not approved for human or animal consumption. Researchers are solely responsible for ensuring their handling, reconstitution, and storage protocols meet all applicable institutional, ethical, and legal standards.
